ProKidney Corp (NAS:PROK)
$ 2.38 -0.02 (-0.83%) Market Cap: 300.00 Mil Enterprise Value: -123.60 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

ProKidney Corp at Bank of America Global Healthcare Conference Transcript

May 09, 2023 / 11:20PM GMT
Release Date Price: $9.1 (-3.19%)
Jason Gerberry
BofA Global Research - Analyst

We're going to get going here at the -- with our next company presenter at the BofA Annual Healthcare Conference. My name is Jason Gerberry. I am one of the Biopharma Analyst here, and I'm pleased to be introducing ProKidney and CEO Tim Bertram. So Tim has some slides he's going to run through. And if time permitting, we may have a time for a little discussion.

Tim Bertram
ProKidney Corp. - CEO & Director

It's perfect. Thank you, Jason. Thank you all of you for coming to hear our story about ProKidney. I thank you for your interest. And hopefully, we'll have some time for questions.

I'll be making forward-looking statements today. You can find the details on this in our website if you want to follow that further.

So what is ProKidney, and what is our real goal and mission? ProKidney is trying to bring a hope to one of the most expensive unmet medical needs that we currently have today, and this is kidney failure.

Why is kidney failure so significant? It is a $130 billion problem

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot